RecruitingNCT05434026

Chinese Colorectal Cancer Database

Sponsor

Beijing Friendship Hospital

Enrollment

200,000 participants

Start Date

Aug 3, 2022

Study Type

OBSERVATIONAL

Conditions

Rectal Cancer Colonic Cancer Prospective Studies

Summary

1. To establish the Chinese people's own clinical data database of colorectal cancer, reflecting the law and characteristics of colorectal cancer patients in China. 2. Based on colorectal cancer surgery, collect clinical data, especially data on clinical manifestations, complications, laboratory tests, auxiliary examinations, postoperative clinical effects, surgical complications, and colorectal cancer recurrence, so as to lead the direction of clinical practice and academic research of colorectal cancer surgery in China. It provides a certain basis for future research on colorectal cancer. 3. Provide academic consultation and data support to national health authorities.

Eligibility

Plain Language Summary

Simplified for easier understanding

This study is building a large Chinese national database of patients with colorectal cancer (colon cancer diagnosed by biopsy) to better understand outcomes, treatment patterns, and long-term survival. Data collected will be used to improve future treatment guidelines. **You may be eligible if:** - You have been diagnosed with colon cancer confirmed by biopsy - You are physically able to undergo surgery - You understand and agree to participate **You may NOT be eligible if:** - You are unable to safely undergo surgery - You have a history of serious mental illness - Your treating doctor determines you should not be enrolled Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

Zhongtao Zhang

Beijing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05434026

Related Trials

Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial

NCT068500901 location

Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy

NCT075610601 location

Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer

NCT075282091 location

Watch and Wait in PD-1 Monoclonal Antibody Treated dMMR/MSI-H Distal Rectal Cancer

NCT046430411 location

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

NCT031909411 location